Vertex has initial success in new diabetes project

Remarkably positive insulin results have arrived from Vertex's first patient in the phase I/II trial of its stem cell therapy against type 1 diabetes.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

The results from the first patient to receive Vertex's treatment for type 1 diabetes, VX-880, a therapy derived from stem cells, have been a cause for celebration for the Boston-based biotech company, it reports in a press release.

The patient's need for daily insulin doses has drastically decreased after they were injected with Vertex's synthetic insulin-producing cell therapy in combination with an immunosuppressive therapy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs